Figure 4.

Talazoparib potentiates the anti-tumour activity of LuTate therapy in vivo. Mice bearing AR42J tumours were treated with 30 MBq LuTate on day 1 alone or in combination with 0.25 mg/kg talazoparib twice daily on days 1–5. (a) Animal body weights were monitored and are expressed as the mean percent change in body weight from day 1 ±SEM. Tumours were measured twice weekly and are presented as (b) mean tumour volume ±SEM (n = 7 animals/group) or (c) Kaplan Meier survival curves where survival endpoint was defined as the time the tumour volume reached 1200 mm³ (right). Tumour volumes are shown until the first mouse was removed from the group due to reaching maximal ethical tumour volume. **P < 0.01, ***P < 0.001. (d) Representative haematoxylin and eosin (H&E) staining and BrdU and ɣ-H2AX immunostaining of AR42J tumours harvested at 72 hr following treatment with LuTate and talazoparib.